Soluble Urokinase Receptor and Chronic Kidney Disease

  • Hayek S
  • Sever S
  • Ko Y
  • et al.
342Citations
Citations of this article
263Readers
Mendeley users who have this article in their library.

Abstract

© 2015 Massachusetts Medical Society. All rights reserved. BACKGROUND: Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients with various conditions. It is unknown whether elevated suPAR levels in patients with normal kidney function are associated with future decline in the estimated glomerular filtration rate (eGFR) and with incident chronic kidney disease. METHODS: We measured plasma suPAR levels in 3683 persons enrolled in the Emory Cardiovascular Biobank (mean age, 63 years; 65% men; median suPAR level, 3040 pg per milliliter) and determined renal function at enrollment and at subsequent visits in 2292 persons. The relationship between suPAR levels and the eGFR at baseline, the change in the eGFR over time, and the development of chronic kidney disease (eGFR <60 ml per minute per 1.73 m2 of body-surface area) were analyzed with the use of linear mixed models and Cox regression after adjustment for demographic and clinical variables. RESULTS: A higher suPAR level at baseline was associated with a greater decline in the eGFR during follow-up; the annual change in the eGFR was -0.9 ml per minute per 1.73 m2 among participants in the lowest quartile of suPAR levels as compared with -4.2 ml per minute per 1.73 m2 among participants in the highest quartile (P<0.001). The 921 participants with a normal eGFR (≥90 ml per minute per 1.73 m2) at baseline had the largest suPAR-related decline in the eGFR. In 1335 participants with a baseline eGFR of at least 60 ml per minute per 1.73 m2, the risk of progression to chronic kidney disease in the highest quartile of suPAR levels was 3.13 times as high (95% confidence interval, 2.11 to 4.65) as that in the lowest quartile. CONCLUSIONS: An elevated level of suPAR was independently associated with incident chronic kidney disease and an accelerated decline in the eGFR in the groups studied.

References Powered by Scopus

A new equation to estimate glomerular filtration rate

20867Citations
N/AReaders
Get full text

Prevalence of chronic kidney disease in the United States

4172Citations
N/AReaders
Get full text

Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention

1670Citations
N/AReaders
Get full text

Cited by Powered by Scopus

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

1532Citations
N/AReaders
Get full text

Senolytic CAR T cells reverse senescence-associated pathologies

642Citations
N/AReaders
Get full text

Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome

469Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Hayek, S. S., Sever, S., Ko, Y.-A., Trachtman, H., Awad, M., Wadhwani, S., … Reiser, J. (2015). Soluble Urokinase Receptor and Chronic Kidney Disease. New England Journal of Medicine, 373(20), 1916–1925. https://doi.org/10.1056/nejmoa1506362

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 76

48%

Researcher 44

28%

Professor / Associate Prof. 30

19%

Lecturer / Post doc 9

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 113

74%

Biochemistry, Genetics and Molecular Bi... 22

14%

Agricultural and Biological Sciences 13

8%

Computer Science 5

3%

Article Metrics

Tooltip
Mentions
Blog Mentions: 2
News Mentions: 3
References: 1

Save time finding and organizing research with Mendeley

Sign up for free